F-Phenibut

Fluorophenibut (F-Phenibut, β-phenyl-γ-aminobutyric acid fluoroderivative) is a fluorinated analog of phenibut — a neuropsychiatric drug developed in the Soviet Union in the 1960s — and a close structural relative of baclofen. F-Phenibut is distinguished from phenibut principally by substantially greater potency: it is estimated to be approximately 5–10 times more potent than phenibut on a weight basis, acting more predominantly at GABA-B receptors rather than phenibut's dual GABA-B and α2δ voltage-gated calcium channel activity.

F-Phenibut produces a characteristic combination of anxiolysis, euphoria, sociability enhancement, and mild stimulation at lower doses, with increasing sedation and motor impairment at higher doses. The GABA-B agonist mechanism — shared with baclofen — is associated with a distinct quality of depressant effect that many users describe as more "social" and less purely sedating than classical benzodiazepines, with a pronounced euphoric component. Community experience across two Reddit posts reflects this, though the small dataset limits conclusions.

F-Phenibut's dependence and withdrawal profile is severe. Regular use, even when spaced out, can rapidly produce tolerance and physical dependence, and the GABA-B withdrawal syndrome is distinct from and in some respects more difficult to manage than benzodiazepine withdrawal. Reports of severe protracted withdrawal following even occasional use have been documented in the medical literature, and F-Phenibut's higher potency amplifies these risks relative to phenibut itself. The frequency of F-Phenibut use should be strictly limited — many harm reduction resources recommend no more than once per week, with the caveat that even weekly use may be insufficient to prevent the development of tolerance and dependence in some individuals.